Irvine, E., Feagan, B., Rochon, J., Archambault, A., Fedorak, R., Groll, A., et al. (1994) Quality of Life: A Valid and Reliable Measure of Therapeutic Efficacy in the Treatment of Inflammatory Bowel Disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology, 106, 287-296.

has been cited by the following article:

• TITLE: Inflammatory Bowel Disease and Quality of Life in King Abdulaziz Medical City

  AUTHORS: Fahad A. Alowais, Yazeed A. Alferayan, Rayed M. Aljehani

  KEYWORDS: HRQOL, Inflammatory Bowel Diseases, IBDQ, Crohn’s Disease, Ulcerative Colitis

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.6 No.1, January 25, 2016

  ABSTRACT: Background: Health Related Quality of life (HRQOL) assessment is an important outcome to measure Inflammatory Bowel Disease (IBD). The aim of this study is to evaluate the effects of IBD in patients’ quality of life in King Abdulaziz Medical City, Riyadh. Methods: This is a cohort study of 32 patients with IBD who were given the Inflammatory Bowel Disease Questionnaire (IBDQ) in the outpatient clinic at King Abdulaziz Medical City, Riyadh during the study period of three months in 2014. Results: In a comparison between patients who have Ulcerative Colitis (UC) in contrast to Crohn’s Disease (CD), we found that the mean score for the IBDQ were 170.94 and 149.69 respectively. The worst score was 65 in CD and the highest was 224 in UC. Comparing the subdivisions of the IBDQ it was found that the bowel and systemic domains were affected mostly by the disease. Conclusion: Inflammatory bowel disease has a major impact on HRQOL of patients in different aspects. CD group has worse HRQOL than UC group. The total score was impacted mostly by the systemic and bowel domains in the IBDQ. Saudi patients were more affected by the disease compared to other countries.